This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Bone Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
2.4%
Earnings growth rate
22.9%
EPS growth rate
| Biotechs Industry Growth | -3.6% |
| Revenue growth rate | 2.7% |
| Return on equity | n/a |
| Net Margin | -521.8% |
| Next Earnings Update | 25 Oct 2022 |
Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Bone Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -10 | 3 | 10 |
| 31 Mar 22 | 2 | -11 | 3 | 11 |
| 31 Dec 21 | 2 | -13 | 3 | 12 |
| 30 Sep 21 | 2 | -13 | 3 | 13 |
| 30 Jun 21 | 2 | -14 | 3 | 14 |
| 31 Mar 21 | 2 | -15 | 3 | 14 |
| 31 Dec 20 | 2 | -16 | 3 | 15 |
| 30 Jun 20 | 1 | -10 | 3 | 9 |
| 31 Mar 20 | 1 | -9 | 3 | 8 |
| 31 Dec 19 | 1 | -8 | 3 | 8 |
| 30 Sep 19 | 2 | -11 | 3 | 12 |
| 30 Jun 19 | 2 | -11 | 4 | 12 |
| 31 Mar 19 | 2 | -13 | 4 | 13 |
| 31 Dec 18 | 3 | -14 | 4 | 13 |
| 30 Sep 18 | 2 | -15 | 4 | 13 |
| 30 Jun 18 | 2 | -15 | 3 | 13 |
| 31 Mar 18 | 2 | -14 | 3 | 13 |
| 31 Dec 17 | 2 | -13 | 3 | 13 |
| 30 Sep 17 | 2 | -13 | 3 | 14 |
| 30 Jun 17 | 2 | -14 | 3 | 14 |
| 31 Mar 17 | 2 | -13 | 3 | 14 |
| 31 Dec 16 | 2 | -13 | 3 | 14 |
| 30 Sep 16 | 2 | -13 | 3 | 14 |
| 30 Jun 16 | 2 | -13 | 4 | 14 |
| 31 Mar 16 | 2 | -13 | 3 | 13 |
| 31 Dec 15 | 2 | -14 | 3 | 13 |
Quality Earnings: BOTHE is currently unprofitable.
Growing Profit Margin: BOTHE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOTHE is unprofitable, but has reduced losses over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare BOTHE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOTHE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.4%).
Return on Equity
High ROE: BOTHE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.